Boehringer to lay off salespeople as Humira biosimilar sales lag

Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s (ABBV.N) blockbuster arthritis treatment Humira.